Compare LBRX & IQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | IQ |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | China |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.0M | 1.0B |
| IPO Year | N/A | 2017 |
| Metric | LBRX | IQ |
|---|---|---|
| Price | $31.92 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $46.60 | $2.91 |
| AVG Volume (30 Days) | 227.2K | ★ 5.7M |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.28 |
| Revenue Next Year | N/A | $3.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $0.95 |
| 52 Week High | $33.47 | $2.76 |
| Indicator | LBRX | IQ |
|---|---|---|
| Relative Strength Index (RSI) | 63.93 | 34.52 |
| Support Level | $26.75 | $0.98 |
| Resistance Level | $33.47 | $1.19 |
| Average True Range (ATR) | 1.73 | 0.04 |
| MACD | 0.33 | 0.00 |
| Stochastic Oscillator | 86.22 | 30.95 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.